Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogens and malignant cells represent broad categories of biological entities that are the primary focus of anti-infective and anti-cancer therapies. Pathogens include bacteria, viruses, fungi, and parasites that cause infectious diseases by invading host tissues and disrupting normal physiological processes (NIH, 2023). Malignant cells are host cells that have undergone genetic mutations leading to uncontrolled growth, evasion of apoptosis, and the ability to metastasize (National Cancer Institute, 2024). While these entities are the ultimate targets of medical intervention, they are not specific molecular targets themselves; rather, they contain numerous specific proteins, nucleic acids, and pathways that drugs are designed to inhibit or modulate (Nature Reviews Drug Discovery, 2006). Therapeutic strategies often aim to exploit biochemical differences between these harmful entities and healthy host cells to achieve selective toxicity and minimize side effects.
Not applicable as a single molecular target; therapeutic agents act on specific molecular components (e.g., enzymes, receptors, nucleic acids) within these entities to exert therapeutic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogens and malignant cells.